$MYGN
MYRIAD GENETICS INC Stock $mygn

$mygn Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000156459020021496 Filed on May 06, 2020

Income Statement

Concept	2020 Q1	2019 Q1	2018 Q4
Revenue	$164.0M	$216.6M	$216.8M
YoY Change	-24.28%	18.3%	15.38%
Cost Of Revenue	$50.10M	$48.60M	$52.10M
YoY Change	3.09%	10.2%	17.34%
Gross Profit	$113.9M	$168.0M	$164.7M
YoY Change	-32.2%	20.86%	14.77%
Gross Profit Margin	69.45%	77.56%	75.97%
Selling, General & Admin	$132.9M	$140.6M	$135.2M
YoY Change	-5.48%	30.31%	25.88%
% of Gross Profit	116.68%	83.69%	82.09%
Research & Development	$19.70M	$21.50M	$22.40M
YoY Change	-8.37%	16.22%	33.33%
% of Gross Profit	17.3%	12.8%	13.6%
Depreciation & Amortization	$2.600M	$3.100M	$2.600M
YoY Change	-16.13%	-13.89%	-31.58%
% of Gross Profit	2.28%	1.85%	1.58%
Operating Expenses	$152.6M	$162.1M	$157.6M
YoY Change	-5.86%	28.24%	26.89%
Operating Profit	-$133.7M	$5.900M	$6.100M
YoY Change	-2366.1%	-57.25%	-3.17%
Interest Expense	$2.300M	$3.200M	$3.400M
YoY Change	-28.13%	540.0%	385.71%
% of Operating Profit		54.24%	55.74%
Other Income/Expense, Net	$2.600M	-$2.600M	-$2.500M
YoY Change	-200.0%	420.0%	257.14%
Pretax Income	-$131.1M	$3.300M	$3.600M
YoY Change	-4072.73%	-75.19%	-35.71%
Income Tax	-$15.90M	-$3.600M	$1.000M
% Of Pretax Income		-109.09%	27.78%
Net Earnings	-$115.2M	$6.900M	$2.600M
YoY Change	-1769.57%	-24.18%	-91.59%
Net Earnings / Revenue	-70.24%	3.19%	1.2%
Basic Earnings Per Share	-$1.55	$0.09	$0.04
Diluted Earnings Per Share	-$1.55	$0.09	$0.03
COMMON SHARES
Basic Shares Outstanding	74.50M shares	73.30	74.20
Diluted Shares Outstanding	74.50M shares	74.90	76.50

Balance Sheet

Concept	2020 Q1	2019 Q1	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$181.5M	$149.7M	$165.4M
YoY Change	21.24%	-4.83%	15.26%
Cash & Equivalents	$121.0M	$84.90M	$90.60M
Short-Term Investments	$60.50M	$64.80M	$74.80M
Other Short-Term Assets	$37.90M	$14.30M	$15.60M
YoY Change	165.03%	3.62%	-14.29%
Inventory	$30.80M	$31.90M	$33.30M
Prepaid Expenses
Receivables	$102.5M	$142.6M	$116.6M
Other Receivables	$2.500M	$4.400M	$5.900M
Total Short-Term Assets	$355.2M	$342.9M	$336.8M
YoY Change	3.59%	3.44%	3.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$37.10M	$58.70M	$59.10M
YoY Change	-36.8%	21.78%	22.11%
Goodwill	$327.1M		$413.2M
YoY Change
Intangibles	$620.0M		$717.6M
YoY Change
Long-Term Investments	$42.80M	$40.30M	$29.90M
YoY Change	6.2%	-21.44%	-48.89%
Other Assets
YoY Change
Total Long-Term Assets	$1.092B	$1.214B	$1.220B
YoY Change	-10.12%	36.91%	35.31%
TOTAL ASSETS
Total Short-Term Assets	$355.2M	$342.9M	$336.8M
Total Long-Term Assets	$1.092B	$1.214B	$1.220B
Total Assets	$1.447B	$1.557B	$1.557B
YoY Change	-7.1%	27.8%	26.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$30.30M	$24.10M	$31.90M
YoY Change	25.73%	19.31%	27.09%
Accrued Expenses	$63.10M	$53.40M	$73.70M
YoY Change	18.16%	9.43%	21.22%
Deferred Revenue	$3.800M	$2.300M	$2.400M
YoY Change	65.22%	-11.54%	-29.41%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$113.2M	$108.9M	$113.3M
YoY Change	3.95%	15.48%	-28.88%
LONG-TERM LIABILITIES
Long-Term Debt	$225.2M	$263.4M	$273.3M
YoY Change	-14.5%	280.09%	532.64%
Other Long-Term Liabilities	$81.80M	$7.300M	$6.600M
YoY Change	1020.55%	7.35%	0.0%
Total Long-Term Liabilities	$225.2M	$270.7M	$279.9M
YoY Change	-16.81%	255.72%	462.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$113.2M	$108.9M	$113.3M
Total Long-Term Liabilities	$225.2M	$270.7M	$279.9M
Total Liabilities	$479.5M	$475.5M	$492.5M
YoY Change	0.84%	75.98%	56.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$118.5M		$22.90M
YoY Change
Common Stock	$1.094B		$1.046B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$967.2M	$1.082B	$1.064B
YoY Change
Total Liabilities & Shareholders Equity	$1.447B	$1.557B	$1.557B
YoY Change	-7.1%	27.8%	26.71%

Cashflow Statement

Concept	2020 Q1	2019 Q1	2018 Q4
OPERATING ACTIVITIES
Net Income	-$115.2M	$6.900M	$2.600M
YoY Change	-1769.57%	-24.18%	-91.59%
Depreciation, Depletion And Amortization	$2.600M	$3.100M	$2.600M
YoY Change	-16.13%	-13.89%	-31.58%
Cash From Operating Activities	$16.80M	$6.600M	$37.80M
YoY Change	154.55%	-42.61%	14.55%
INVESTING ACTIVITIES
Capital Expenditures	-$3.000M	-$3.100M	-$2.800M
YoY Change	-3.23%	6.9%	33.33%
Acquisitions
YoY Change
Other Investing Activities	$26.30M	-$700.0K	-$5.300M
YoY Change	-3857.14%	-131.82%	112.0%
Cash From Investing Activities	$23.20M	-$3.800M	-$8.100M
YoY Change	-710.53%	442.86%	76.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$200.0K	-9.400M	-32.60M
YoY Change	-102.13%	118.6%	24.9%
NET CHANGE
Cash From Operating Activities	$16.80M	6.600M	37.80M
Cash From Investing Activities	$23.20M	-3.800M	-8.100M
Cash From Financing Activities	$200.0K	-9.400M	-32.60M
Net Change In Cash	$39.80M	-6.600M	-2.900M
YoY Change	-703.03%	-201.54%	-226.09%
FREE CASH FLOW
Cash From Operating Activities	$16.80M	$6.600M	$37.80M
Capital Expenditures	-$3.000M	-$3.100M	-$2.800M
Free Cash Flow	$19.80M	$9.700M	$40.60M
YoY Change	104.12%	-32.64%	15.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	25600000
	us-gaap	Revenue Practical Expedient Remaining Performance Obligation RevenuePracticalExpedientRemainingPerformanceObligation	true
	us-gaap	Revenue Practical Expedient Initial Application And Transition Nondisclosure Of Transaction Price Allocation To Remaining Performance Obligation RevenuePracticalExpedientInitialApplicationAndTransitionNondisclosureOfTransactionPriceAllocationToRemainingPerformanceObligation	true
	us-gaap	Revenue Practical Expedient Incremental Cost Of Obtaining Contract RevenuePracticalExpedientIncrementalCostOfObtainingContract	true
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	42800000
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12900000
CY2019Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	21700000
CY2020Q1	us-gaap	Goodwill Goodwill	327100000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	1088900000
CY2020Q1	us-gaap	Assets Current AssetsCurrent	355200000
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37100000
CY2020Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	620000000.0
CY2020Q1	us-gaap	Assets Assets	1446700000
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	64500000
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1088900000
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1562700000
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	30300000
CY2019Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1068000000.0
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5400000
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	63100000
CY2020Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	3100000
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3800000
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	113200000
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	117800000
CY2020Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	22300000
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	55900000
CY2019Q2	mygn	Liabilities Other Than Long Term Debt Noncurrent Excluding Business Combination Contingent Consideration Liability Noncurrent LiabilitiesOtherThanLongTermDebtNoncurrentExcludingBusinessCombinationContingentConsiderationLiabilityNoncurrent	7800000
CY2020Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3600000
CY2019Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10400000
CY2020Q1	us-gaap	Long Term Debt LongTermDebt	225200000
CY2019Q2	us-gaap	Long Term Debt LongTermDebt	233500000
CY2020Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	59300000
CY2019Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	82600000
CY2020Q1	us-gaap	Liabilities Liabilities	479500000
CY2019Q2	us-gaap	Liabilities Liabilities	473800000
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74500000
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73500000
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	700000
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	700000
CY2020Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1092800000
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7800000
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118500000
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	967200000
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	967200000
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1446700000
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	164000000.0
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21500000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	59800000
CY2020Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3400000
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	132900000
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	140600000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	402700000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	405700000
CY2020Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	98400000
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	99700000
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	297700000
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	210700000
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-133700000
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	5900000
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	800000
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	700000
CY2020Q1	us-gaap	Interest Expense InterestExpense	2300000
CY2019Q1	us-gaap	Interest Expense InterestExpense	3200000
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4100000
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-100000
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2600000
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-131100000
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15900000
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-115200000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-100000
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.55
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.55
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74500000
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74500000
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-100000
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2500000
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-117800000
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-117800000
CY2018Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	966100000
CY2018Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	127400000
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7700000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-700000
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-200000
CY2018Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1102200000
CY2018Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2600000
CY2018Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7500000
CY2018Q4	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	-50000000.0
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	2600000
CY2018Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-700000
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1064200000
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1900000
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9500000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	6900000
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-700000
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1081800000
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1088900000
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8800000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-20600000
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2100000
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1074500000
CY2019Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1800000
CY2019Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7000000.0
CY2019Q4	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	100000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-8300000
CY2019Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2200000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1077300000
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	200000
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7500000
CY2020Q1	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-100000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-115200000
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	100000
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2600000
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	967200000
	us-gaap	Net Income Loss NetIncomeLoss	-144100000
	us-gaap	Net Income Loss NetIncomeLoss	8800000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	54300000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	54600000
	mygn	Non Cash Interest Expense NonCashInterestExpense	300000
	mygn	Non Cash Interest Expense NonCashInterestExpense	300000
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	1000000.0
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	200000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	900000
	us-gaap	Share Based Compensation ShareBasedCompensation	23300000
	us-gaap	Share Based Compensation ShareBasedCompensation	24700000
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	22900000
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-3000000.0
	mygn	Increase Decrease In Unrecognized Tax Benefits IncreaseDecreaseInUnrecognizedTaxBenefits	-600000
	mygn	Increase Decrease In Unrecognized Tax Benefits IncreaseDecreaseInUnrecognizedTaxBenefits	7300000
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	99700000
	mygn	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	2800000
	mygn	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-1400000
	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	1500000
	mygn	Increase Decrease In Prepaid Expense Excluding Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidExpenseExcludingIncreaseDecreaseInPrepaidTaxes	-3500000
	mygn	Increase Decrease In Prepaid Expense Excluding Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidExpenseExcludingIncreaseDecreaseInPrepaidTaxes	-2000000.0
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-29500000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	27000000.0
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-900000
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	400000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-7400000
	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	300000
	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	3000000.0
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2100000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-8100000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-15400000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1400000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1800000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-400000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	30700000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	52200000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	7800000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	7200000
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	278500000
	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	21300000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	60800000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	57000000.0
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	56300000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	51800000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9000000.0
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-290900000
	mygn	Proceeds From Repayments Of Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromRepaymentsOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1500000
	mygn	Proceeds From Repayments Of Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromRepaymentsOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6500000
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	3900000
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	340000000.0
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	8600000
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	85000000.0
	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	1400000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	50000000.0
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11000000.0
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	210100000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-900000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	2600000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	27800000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26000000.0
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93200000
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110900000
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	121000000.0
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84900000
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.46%;white-space:nowrap" valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td> <td valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">BASIS OF PRESENTATION</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements have been prepared by Myriad Genetics, Inc. (the “Company” or “Myriad”) in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The condensed consolidated financial statements herein should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2019, included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019. Operating results for the three and nine months ended March 31, 2020 may not necessarily be indicative of results to be expected for any other interim period or for the full year.</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of the Company’s majority-owned subsidiary, Assurex Canada, Ltd. which is 85% owned by Assurex Health, Inc. (“Assurex”), a wholly owned subsidiary of the Company, and 15% owned by the Centre for Addiction and Mental Health. Assurex Canada, Ltd. is a consolidated subsidiary of Assurex Health, Inc. The value of the non-controlling interest represents the portion of Assurex Canada, Ltd.’s profit or loss and net assets that is not held by Assurex Health, Inc. The Company attributes comprehensive income or loss of the subsidiary between the Company and the non-controlling interest based on the respective ownership interest.</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain immaterial prior period goodwill impairment charges that were previously classified as part of selling, general and administrative expense in the condensed consolidated statements of operations were reclassified to conform to the current period presentation and are included as part of the goodwill and intangible asset impairment charges financial statement line item in the current period. </p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Adopted Standards </p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and changing certain lessor accounting requirements. ASU 2016-02 also requires entities to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. On July 1, 2019, the Company adopted ASU 2016-02 under the modified retrospective approach by initially applying ASU 2016-02 at the adoption date, rather than at the beginning of the earliest comparative period presented. Results for the three and nine months ended March 31, 2020 are presented under ASU 2016-02. Prior period amounts were not adjusted and continue to be reported under previous lease accounting guidance.</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASU 2016-02, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (“ROU”) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the implicit rate in the Company's leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating the Company’s incremental borrowing rates, the Company gives consideration to its credit risk, term of the lease, total lease payments and adjust for the impacts of collateral, as necessary. The lease term used may reflect any option to extend or terminate the lease when it is reasonably certain the Company will exercise such options. Lease expenses for the Company's operating leases are recognized on a straight-line basis over the lease term.</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2016-02 provides a number of optional practical expedients in transitioning to ASU 2016-02. The Company has elected the package of practical expedients to avoid reassessing under ASU 2016-02 prior conclusions about lease identification, lease classification and initial direct costs. The Company has also elected the practical expedient allowing the use of hindsight in </p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determining the lease term and assessing impairment of right-of-use ROU assets based on all facts and circumstances through the effective date of the new standard. ASU 2016-02 also provides practical expedients for ongoing lease accounting. The Company has elected the recognition exemption for short-term leases for all leases that qualify. Under this exemption, the Company will not recognize ROU assets or lease liabilities for those leases that qualify as a short-term lease (leases with lease terms of 12 months or less), which includes not recognizing ROU assets or lease liabilities for existing short-term leases in transition. The Company also has elected the practical expedient to avoid separating lease and non-lease components for any of its leases within its existing classes of assets.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the July 1, 2019 adoption date, the Company recognized operating lease liabilities of $78.8 and right-of-use assets related to operating leases totaling $74.5 as of the adoption date. These are presented as “Current maturities of operating lease liabilities” for a total of $13.1, “Noncurrent operating lease liabilities” for a total of $65.7, and “Operating lease right-of-use assets” for a total of $74.5 on the Company’s consolidated balance sheet. <span style="color:#000000;">No adjustments to the beginning retained earnings balance were required.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 1, 2019, the Company early adopted ASU 2017-04, Intangibles – Goodwill and Other (Topic 350) (“ASU 2017-04”) as permitted under the standard. The standard simplifies the accounting for goodwill impairment by requiring a goodwill impairment to be measured using a single step impairment model, whereby the impairment equals the difference between the carrying amount and the fair value of the specified reporting units as a whole. This eliminates the second step of the current impairment model that requires a company to first estimate the fair value of all assets in a reporting unit and measure impairments based on those fair values and a residual measurement approach. The standard also specifies that any loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This ASU was adopted on a prospective basis with no material impact to the Company’s consolidated financial statements. </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Standards Effective in Future Years and Not Yet Adopted</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.46%;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) (“ASU 2016-13”) which introduces new guidance for the accounting for credit losses on certain instruments within its scope. ASU 2016-13 introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. For trade receivables, the Company will be required to use a forward-looking expected loss model rather than the incurred loss model for recognizing credit losses, which reflects losses that are probable. Credit losses relating to available-for-sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. ASU 2016-13 is effective for fiscal years beginning after December 31, 2019, including interim periods within those years. Early application of the guidance is permitted for all entities for fiscal years beginning after December 15, 2018, including the interim periods within those fiscal years. Application of the amendments is through a cumulative-effect adjustment to retained earnings as of the effective date. The Company is currently evaluating the impact of ASU 2016-13 on its consolidated financial statements<span style="color:#000000;">. </span></p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software, including hosting arrangements that include an internal-use software license. This guidance is effective for public entities for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the potential effects of this guidance on its consolidated financial statements.</p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain immaterial prior period goodwill impairment charges that were previously classified as part of selling, general and administrative expense in the condensed consolidated statements of operations were reclassified to conform to the current period presentation and are included as part of the goodwill and intangible asset impairment charges financial statement line item in the current period. </p>
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	164000000.0
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	216600000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	545400000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	635700000
CY2019Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2200000
CY2018Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2600000
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2400000
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5900000
	mygn	Contract With Customer Liability Prepayments ContractWithCustomerLiabilityPrepayments	4000000.0
	mygn	Contract With Customer Liability Prepayments ContractWithCustomerLiabilityPrepayments	5600000
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3800000
CY2019Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2300000
CY2019Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	117100000
CY2020Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	142300000
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	169200000
CY2020Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	105200000
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	111900000
CY2020Q1	mygn	Earnings Per Share Increase Decrease Reduction Performance Obligation EarningsPerShareIncreaseDecreaseReductionPerformanceObligation	-0.06
CY2020Q1	mygn	Investments And Cash At Fair Value InvestmentsAndCashAtFairValue	224300000
	us-gaap	Revenue Practical Expedient Remaining Performance Obligation Description RevenuePracticalExpedientRemainingPerformanceObligationDescription	In accordance with ASU 2014-09, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of Company’s performance to date. However, the Company periodically enters into arrangements with customers to provide diagnostic testing and/or pharmaceutical and clinical services that may have terms longer than one year and include multiple performance obligations.
CY2020Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	4100000
CY2020Q1	us-gaap	Capitalized Contract Cost Gross CapitalizedContractCostGross	0
	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payments terms have a payback period of less than one year.
CY2020Q1	mygn	Revenue Increase Decrease Reduction Performance Obligation RevenueIncreaseDecreaseReductionPerformanceObligation	-5500000
	mygn	Revenue Increase Decrease Reduction Performance Obligation RevenueIncreaseDecreaseReductionPerformanceObligation	-10800000
	mygn	Earnings Per Share Increase Decrease Reduction Performance Obligation EarningsPerShareIncreaseDecreaseReductionPerformanceObligation	-0.11
CY2020Q1	us-gaap	Investments And Cash InvestmentsAndCash	223800000
CY2020Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	223800000
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	700000
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	200000
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	224300000
CY2019Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	191200000
CY2019Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	600000
CY2020Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	60200000
CY2020Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	60500000
CY2020Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	42600000
CY2020Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	42800000
CY2020Q1	us-gaap	Investments And Cash InvestmentsAndCash	223800000
CY2020Q1	mygn	Investments And Cash At Fair Value InvestmentsAndCashAtFairValue	224300000
CY2019Q2	us-gaap	Land Land	2300000
CY2019Q2	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	18800000
CY2020Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	31100000
CY2019Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	31000000.0
CY2020Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	111200000
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37100000
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57300000
CY2020Q1	us-gaap	Depreciation Depreciation	2600000
CY2019Q1	us-gaap	Depreciation Depreciation	3100000
	us-gaap	Depreciation Depreciation	8500000
	us-gaap	Depreciation Depreciation	10600000
CY2020Q1	us-gaap	Goodwill Goodwill	327100000
CY2020Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	4800000
CY2019Q2	us-gaap	Goodwill Goodwill	417200000
	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	7300000
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	82000000.0
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-800000
CY2020Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	822500000
CY2020Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	207300000
CY2020Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	615200000
CY2020Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	4800000
CY2020Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	827300000
CY2020Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	207300000
CY2020Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	620000000.0
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15300000
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15200000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	45800000
CY2019Q2	mygn	Other Liabilities Noncurrent Other OtherLiabilitiesNoncurrentOther	1000000.0
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7800000
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	78900000
CY2020Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	226600000
CY2020Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	55300000
CY2019Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	48800000
CY2020Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	3500000
CY2019Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	3000000.0
CY2019Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	9100000
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4300000
CY2019Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	18000000.0
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	63100000
CY2020Q1	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	1400000
CY2020Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	225200000
CY2019Q2	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	6800000
CY2019	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	4500000
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70600000
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	1000000.0
CY2019	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	1600000
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74500000
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73500000
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73500000
CY2020Q1	mygn	Number Of Defined Benefit Pension Plans NumberOfDefinedBenefitPensionPlans	2
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000.0
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000.0
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74500000
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73500000
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73500000
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70600000
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74500000
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73300000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74200000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73500000
CY2019Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1600000
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2900000
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74500000
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74900000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74200000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	76400000
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	400000
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1000000.0
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	900000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	700000
CY2020Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	110700000
	mygn	Amount Of Reduction In Common Stock As Result Of Stock Repurchases AmountOfReductionInCommonStockAsResultOfStockRepurchases	16900000
	mygn	Amount Charged To Retained Earnings As Result Of Stock Repurchases AmountChargedToRetainedEarningsAsResultOfStockRepurchases	33100000
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15900000
CY2020Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.121
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3600000
CY2019Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	1.091
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	Options and RSUs granted to our non-employee directors vest in full upon completion of one year of service on the Board following the date of the grant
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5500000
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	24.45
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	400000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	22.93
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	300000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	26.78
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4800000
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0387
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	24.43
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4800000
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	24.43
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7500000
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9500000
	us-gaap	Share Based Compensation ShareBasedCompensation	23300000
	us-gaap	Share Based Compensation ShareBasedCompensation	24700000
CY2020Q1	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	113900000
CY2019Q2	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	104500000
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	13800000
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	3900000
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-2800000
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Other Comprehensive Income FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome	-400000
CY2020Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	6700000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3900000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	14700000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	13500000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	12300000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	12100000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	19300000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	75800000
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y6M
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-133700000
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	15100000
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	14100000
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	13100000
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	12200000
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	11900000
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	19100000
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	85500000
	mygn	Percent Of Employee Contribution To Deferred Savings Plan PercentOfEmployeeContributionToDeferredSavingsPlan	0.50
	mygn	Employers Contribution Not To Exceed Percentage Of Employees Compensation EmployersContributionNotToExceedPercentageOfEmployeesCompensation	0.04
CY2020Q1	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	2200000
CY2019Q1	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	2300000
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	6800000
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	6000000.0
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	164000000.0
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	17900000
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	216600000
CY2019Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18300000
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	5900000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	545400000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	54300000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-163400000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	635700000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	54600000
	us-gaap	Operating Income Loss OperatingIncomeLoss	13200000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-115200000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	6900000
	us-gaap	Interest Paid Net InterestPaidNet	7300000
	us-gaap	Interest Paid Net InterestPaidNet	9100000
CY2020Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4300000
CY2019Q1	us-gaap	Profit Loss ProfitLoss	6900000
	us-gaap	Net Income Loss NetIncomeLoss	-144100000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1000000.0
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-115200000
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	5900000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-163400000
	us-gaap	Operating Income Loss OperatingIncomeLoss	13200000
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	800000
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	700000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2500000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2300000
CY2020Q1	us-gaap	Interest Expense InterestExpense	2300000
CY2019Q1	us-gaap	Interest Expense InterestExpense	3200000
	us-gaap	Interest Expense InterestExpense	7700000
	us-gaap	Interest Expense InterestExpense	8800000
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4100000
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-100000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3800000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000000.0
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-131100000
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3300000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-164800000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7700000
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15900000
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3600000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-20700000
	us-gaap	Profit Loss ProfitLoss	-144100000
	us-gaap	Profit Loss ProfitLoss	8700000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-100000
	us-gaap	Net Income Loss NetIncomeLoss	8800000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	400000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	5300000

Files In Submission

Name	View Source	Status
0001564590-20-021496-index-headers.html	Edgar Link	pending
0001564590-20-021496-index.html	Edgar Link	pending
0001564590-20-021496.txt	Edgar Link	pending
0001564590-20-021496-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gw44lqkdkezg000001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mygn-10q_20200331.htm	Edgar Link	pending
mygn-10q_20200331_htm.xml	Edgar Link	completed
mygn-20200331.xsd	Edgar Link	pending
mygn-20200331_cal.xml	Edgar Link	unprocessable
mygn-20200331_def.xml	Edgar Link	unprocessable
mygn-20200331_lab.xml	Edgar Link	unprocessable
mygn-20200331_pre.xml	Edgar Link	unprocessable
mygn-ex101_182.htm	Edgar Link	pending
mygn-ex311_8.htm	Edgar Link	pending
mygn-ex321_6.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MYGN
MYRIAD GENETICS INC Stock $mygn

2020 Q1 Form 10-Q Financial Statement

#000156459020021496 Filed on May 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MYGN MYRIAD GENETICS INC Stock $mygn

2020 Q1 Form 10-Q Financial Statement

#000156459020021496 Filed on May 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MYGN
MYRIAD GENETICS INC Stock $mygn